Pfizer Reports meta-analysis Data for Ciltacabtagene autoleucel in Myelodysplastic syndrome

Pfizer today announced meta-analysis results for Ciltacabtagene autoleucel in patients with Myelodysplastic syndrome. The study demonstrated that Ciltacabtagene autoleucel reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Myelodysplastic syndrome and support the continued development of Ciltacabtagene autoleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ciltacabtagene autoleucel was consistent with previous observations, with no new safety signals identified.